Physician profile
Shannon Mcmann
NPI 1376692855
$5,902.17
in general payments reported to CMS, 2019-2025
36 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $255 · 2021: $718 · 2022: $920 · 2023: $1,102 · 2024: $1,333 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,677.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,011.63 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $953.53 | 2021-2025 | |
| Genzyme Corporation | $860.67 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $380.94 | 2020-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $327.61 | 2024-2025 | Airsupra |
| Lilly USA, LLC | $267.70 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Emd Serono, INC. | $191.07 | 2022-2023 | |
| Nevro Corp. | $169.21 | 2024 | Senza |
| Biohaven Pharmaceutical Holding Company Ltd. | $161.82 | 2022 | |
| Sanofi-Aventis U.S. LLC | $152.43 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $147.21 | 2023-2025 | Opsumit, Uptravi |
| Teva Pharmaceuticals USA, INC. | $137.87 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $124.74 | 2023 | |
| Amgen INC. | $124.46 | 2019-2024 | Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $107.54 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $106.14 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.93 | 2021-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $64.58 | 2019 | |
| Portola Pharmaceuticals, LLC | $63.79 | 2019 | |
| Glaxosmithkline, LLC. | $57.99 | 2022-2024 | Trelegy Ellipta |
| Cook Medical LLC | $48.02 | 2024-2025 | Lunderquist, Zenith, Zenith Spiral-Z |
| Acera Surgical, INC. | $47.67 | 2024-2025 | Restrata Wound Matrix |
| Biohaven Pharmaceuticals, INC. | $37.24 | 2021 | |
| Access Pro Medical, LLC | $34.69 | 2025 | Matriderm |
| Coloplast Corp | $28.91 | 2023-2025 | Porges Coloplast |
| Polynovo North America LLC | $26.33 | 2024 | Novosorb Btm |
| Organogenesis INC. | $24.03 | 2025 | Puraply Wound Matrix |
| Abbott Laboratories | $22.10 | 2023 | Jeti |
| Mimedx Group, INC. | $21.98 | 2024 | |
| Neuros Medical, INC. | $19.78 | 2025 | Altius |
| Bioventus LLC | $18.48 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.79 | 2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $15.45 | 2025 | Cologuard Collection Kit |
| Cardiva Medical, INC. | $15.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.45 | 2019 | |
| Pfizer INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Mcmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.